Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity
- PMID: 25313013
- DOI: 10.1111/ane.12331
Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity
Abstract
Objectives: Thermal quantitative sensory testing (QST) is a non-invasive procedure helpful in the assessment of the function of small Aδ and C nerve sensory fibres. Oxaliplatin (OXA) is an effective chemotherapeutic agent, but is frequently associated with neurotoxic dose-limiting side effects. This controlled clinical trial evaluated the reliability and accuracy of thermal QST for assessing the OXA-induced acute neuropathic syndrome, whose clinical hallmark is cold-triggered painful paraesthesia.
Materials & methods: A testing protocol with the Thermal Sensory Analyzer (Medoc) was carried out in 20 colorectal cancer patients during the initial four cycles of OXA-based chemotherapy and in 20 age- and sex-matched healthy volunteers. Testing was carried out on the hands and included the determination of thermal detection and pain thresholds and the intensity of pain evoked by cold stimuli. Calculations were made of: coefficients of test-retest and inter-rater reliability, indices of responsiveness and parameters that quantify diagnostic accuracy.
Results: Thermal thresholds showed moderate to good reliability (ρ ≥ 0.383), but were not consistently responsive to the effects of chemotherapy (cold pain thresholds decreased in both groups, although almost twice in patients compared to healthy volunteers). Conversely, the intensity of pain evoked by suprathreshold cold stimuli was reliable (ρ ≥ 0.822), responsive (detected changes over time) and discriminated between patients and healthy volunteers (area under the ROC curve = 0.700).
Conclusions: The procedure was reliable and accurate to evaluate cold hyperalgesia resulting from OXA administration. The data provided may be used to define efficacy endpoints for future clinical trials of therapies for OXA-induced neuropathies and calculate appropriate sample sizes.
Keywords: chemotherapy; colorectal neoplasms; neuropathic pain; neurotoxicity; reproducibility of results; sensitivity and specificity; thermal allodynia; thermal hyperalgesia.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study.Pain. 2009 Aug;144(3):245-252. doi: 10.1016/j.pain.2009.03.024. Epub 2009 May 19. Pain. 2009. PMID: 19457614 Clinical Trial.
-
Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.Clin Colorectal Cancer. 2016 Mar;15(1):37-46. doi: 10.1016/j.clcc.2015.07.001. Epub 2015 Jul 26. Clin Colorectal Cancer. 2016. PMID: 26337211
-
Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.Clin Neurophysiol. 2018 Mar;129(3):694-706. doi: 10.1016/j.clinph.2017.11.015. Epub 2017 Nov 26. Clin Neurophysiol. 2018. PMID: 29233604
-
[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].Schmerz. 2008 Feb;22(1):16-23. doi: 10.1007/s00482-007-0552-5. Schmerz. 2008. PMID: 17578604 Review. German.
-
[Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy].Yakugaku Zasshi. 2016;136(2):287-96. doi: 10.1248/yakushi.15-00214. Yakugaku Zasshi. 2016. PMID: 26831807 Review. Japanese.
Cited by
-
Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.Asian Pac J Cancer Prev. 2021 Mar 1;22(3):705-709. doi: 10.31557/APJCP.2021.22.3.705. Asian Pac J Cancer Prev. 2021. PMID: 33773532 Free PMC article. Clinical Trial.
-
Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathy.J Neurol. 2022 Aug;269(8):4174-4184. doi: 10.1007/s00415-022-11035-9. Epub 2022 Mar 8. J Neurol. 2022. PMID: 35258850 Free PMC article.
-
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncol Ther. 2021 Dec;9(2):385-450. doi: 10.1007/s40487-021-00168-y. Epub 2021 Oct 16. Oncol Ther. 2021. PMID: 34655433 Free PMC article. Review.
-
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity.J Pers Med. 2021 Jul 16;11(7):669. doi: 10.3390/jpm11070669. J Pers Med. 2021. PMID: 34357136 Free PMC article. Review.
-
Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy.Neural Regen Res. 2018 May;13(5):775-778. doi: 10.4103/1673-5374.232459. Neural Regen Res. 2018. PMID: 29862996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources